DE2611690A1
(de)
*
|
1976-03-19 |
1977-09-22 |
Goedecke Ag |
Cyclische sulfonyloxyimide
|
JPS5776189U
(xx)
*
|
1980-10-28 |
1982-05-11 |
|
|
JPS5847580U
(ja)
*
|
1981-09-28 |
1983-03-30 |
本田技研工業株式会社 |
車両用荷物箱の取付構造
|
JPS6152583U
(xx)
*
|
1984-09-11 |
1986-04-09 |
|
|
JPS61139881U
(xx)
*
|
1985-02-21 |
1986-08-29 |
|
|
US4876279A
(en)
*
|
1986-05-05 |
1989-10-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4960931A
(en)
*
|
1988-05-02 |
1990-10-02 |
Warner-Lambert Company |
Gabapentin mohohydrate and a process for producing the same
|
US4894476A
(en)
*
|
1988-05-02 |
1990-01-16 |
Warner-Lambert Company |
Gabapentin monohydrate and a process for producing the same
|
YU162789A
(en)
*
|
1988-09-01 |
1990-12-31 |
Lonza Ag |
2-aza-4-(alcoxycarbonyl) spiro/4,5/decan-3-ones
|
DE3928183A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Lactamfreie cyclische aminosaeuren
|
MY106864A
(en)
*
|
1989-08-25 |
1995-08-30 |
Warner Lambert Co |
Improved process for cyclic amino acid anticonvulsant compounds.
|
US5319135A
(en)
*
|
1989-08-25 |
1994-06-07 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
US5132451A
(en)
*
|
1989-08-25 |
1992-07-21 |
Warner-Lambert Company |
Process for cyclic amino acid anticonvulsant compounds
|
DE3928182A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von gabapentin
|
DE3928184A1
(de)
*
|
1989-08-25 |
1991-02-28 |
Goedecke Ag |
Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
|
FI905584A
(fi)
*
|
1989-11-16 |
1991-05-17 |
Lonza Ag |
Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
|
US5157138A
(en)
*
|
1989-11-16 |
1992-10-20 |
Pfizer, Inc. |
Glutaric acid derivatives and preparation thereof
|
US5260467A
(en)
*
|
1989-11-16 |
1993-11-09 |
Pfizer Inc. |
Glutaric acid derivatives and preparation thereof
|
GB8925933D0
(en)
*
|
1989-11-16 |
1990-01-04 |
Pfizer Ltd |
Glutaric acid derivatives and preparation thereof
|
US5149870A
(en)
*
|
1989-11-16 |
1992-09-22 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl)cyclohexane acetic acid
|
US5136091A
(en)
*
|
1989-11-16 |
1992-08-04 |
Lonza Ltd. |
Process for the production of 1-(aminomethyl) cyclohexane acetic acid
|
US5084479A
(en)
*
|
1990-01-02 |
1992-01-28 |
Warner-Lambert Company |
Novel methods for treating neurodegenerative diseases
|
US5025035A
(en)
*
|
1990-10-12 |
1991-06-18 |
Warner-Lambert Company |
Method of treating depression
|
US5792796A
(en)
*
|
1994-07-27 |
1998-08-11 |
Warner-Lambert Company |
Methods for treating anxiety and panic
|
US5510381A
(en)
*
|
1995-05-15 |
1996-04-23 |
Warner-Lambert Company |
Method of treatment of mania and bipolar disorder
|
AU720628B2
(en)
*
|
1996-02-07 |
2000-06-08 |
Warner-Lambert Company |
Novel cyclic amino acids as pharmaceutical agents
|
NZ331143A
(en)
*
|
1996-03-14 |
2001-06-29 |
Warner Lambert Co |
Substituted cyclic amino acids as pharmaceutical agents
|
NZ331142A
(en)
*
|
1996-03-14 |
2001-04-27 |
Warner Lambert Co |
Bridged cyclic amino acids as pharmaceutical agents
|
CN1094757C
(zh)
|
1996-07-24 |
2002-11-27 |
沃尼尔·朗伯公司 |
用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物
|
BR9712651A
(pt)
*
|
1996-10-23 |
1999-10-26 |
Warner Lambert Co |
cidos gama-aminobutìricos substituìdos com agentes farmacêuticos.
|
US6255526B1
(en)
|
1996-12-24 |
2001-07-03 |
Teva Pharmaceutical Industries Ltd. |
Preparation of gabapentin
|
IL119890A
(en)
*
|
1996-12-24 |
2002-03-10 |
Teva Pharma |
Gabapentin form iii and preparation of gabapentin form ii
|
HRP980342A2
(en)
*
|
1997-06-25 |
1999-02-28 |
Warner Lambert Co |
Anti-inflammatory method
|
US6329429B1
(en)
|
1997-06-25 |
2001-12-11 |
Warner-Lambert Company |
Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
|
US6194459B1
(en)
|
1997-08-19 |
2001-02-27 |
Warner-Lambert Company |
Methods for treating physiological conditions associated with the use, or sequelae of use, of ***e or other psychomotors stimulants
|
ATE311867T1
(de)
*
|
1997-09-08 |
2005-12-15 |
Warner Lambert Co |
Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
|
AU9318398A
(en)
|
1997-10-07 |
1999-04-27 |
Warner-Lambert Company |
Process for preparing a cyclic amino acid anticonvulsant compound
|
PL199794B1
(pl)
*
|
1997-10-27 |
2008-10-31 |
Warner Lambert Co |
Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów
|
US6984659B2
(en)
*
|
1997-11-18 |
2006-01-10 |
Klinikum Der Albert-Ludwigs Universitaet |
2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
|
CN1210268C
(zh)
|
1997-12-16 |
2005-07-13 |
沃尼尔·朗伯公司 |
((环)烷基取代的)-γ-氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
|
AU759392B2
(en)
|
1997-12-16 |
2003-04-10 |
Warner-Lambert Company |
4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
|
PL341291A1
(en)
|
1997-12-16 |
2001-04-09 |
Warner Lambert Co |
1-substituted derivatives of 1-aminomethyl-ccycloalkanes (gabapentin analogues), their production and application of them in treating neurological disorders
|
WO1999037296A1
(en)
*
|
1998-01-23 |
1999-07-29 |
Warner-Lambert Company |
Gabapentin and its derivatives for the treatment of muscular and skeletal pain
|
EP0974351A3
(en)
*
|
1998-04-24 |
2000-12-13 |
Jouveinal |
Medicament for preventing and treating gastrointestinal damage
|
PL204921B1
(pl)
|
1998-05-15 |
2010-02-26 |
Warner Lambert Co |
Stabilizowana kompozycja farmaceutyczna zawierająca 4-amino-3-podstawioną pochodną kwasu butanowego i α-aminokwas oraz sposób jej wytwarzania
|
WO1999059572A1
(en)
*
|
1998-05-15 |
1999-11-25 |
Warner-Lambert Company |
Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
|
ES2137137B1
(es)
*
|
1998-05-25 |
2000-08-16 |
Medichem Sa |
Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
|
JP2002516312A
(ja)
|
1998-05-26 |
2002-06-04 |
ワーナー−ランバート・カンパニー |
カルシウムチャンネルのα2δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
|
ITMI981535A1
(it)
*
|
1998-07-03 |
2000-01-03 |
Zambon Spa |
Processo per la preparazione di gabapentina
|
US20030045500A1
(en)
*
|
1998-07-09 |
2003-03-06 |
Leslie Magnus |
Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
|
FR2781793B1
(fr)
|
1998-08-03 |
2001-07-20 |
Prographarm Lab |
Procede de fabrication de granules de gabapentine enrobes
|
HU225502B1
(en)
*
|
1998-12-29 |
2007-01-29 |
Richter Gedeon Vegyeszet |
Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
|
IT1311984B1
(it)
|
1999-03-26 |
2002-03-22 |
Bioindustria Lab Italiano Medi |
Procedimento per la preparzione di gabapentin.
|
EP1169060B1
(en)
*
|
1999-04-09 |
2005-08-31 |
Euro-Celtique S.A. |
Sodium channel blocker compositions and the use thereof
|
ATE287880T1
(de)
*
|
1999-05-28 |
2005-02-15 |
Warner Lambert Co |
3-heteroarylalkyl-substituierte gaba-analoga
|
US6710190B1
(en)
|
1999-05-28 |
2004-03-23 |
Warner-Lambert Company |
3-heteroarylalkyl substituted gaba analogs
|
US7164034B2
(en)
*
|
1999-06-10 |
2007-01-16 |
Pfizer Inc. |
Alpha2delta ligands for fibromyalgia and other disorders
|
CN1196671C
(zh)
*
|
1999-06-10 |
2005-04-13 |
沃尼尔·朗伯公司 |
单和双取代的3-丙基-γ-氨基丁酸
|
US20080207755A1
(en)
*
|
2000-05-31 |
2008-08-28 |
Pfizer Inc |
Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
|
US6294198B1
(en)
|
1999-08-24 |
2001-09-25 |
Purepac Pharmaceutical Co. |
Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
|
HN2000000224A
(es)
*
|
1999-10-20 |
2001-04-11 |
Warner Lambert Co |
Aminoacidos biciclicos como agentes farmaceuticos
|
GB2362646A
(en)
*
|
2000-05-26 |
2001-11-28 |
Warner Lambert Co |
Cyclic amino acid derivatives useful as pharmaceutical agents
|
EP1384473A1
(en)
*
|
2000-06-16 |
2004-01-28 |
Teva Pharmaceutical Industries Ltd. |
Stable gabapentin containing more than 20 ppm of chlorine ion
|
PL363155A1
(en)
*
|
2000-06-16 |
2004-11-15 |
Teva Pharmaceutical Industries, Ltd. |
Stable gabapentin having ph within a controlled range
|
WO2001097612A1
(en)
|
2000-06-16 |
2001-12-27 |
Teva Pharmaceutical Industries Ltd. |
Stable gabapentin containing more than 2o ppm of chlorine ion
|
WO2002000209A2
(en)
*
|
2000-06-26 |
2002-01-03 |
Warner-Lambert Company |
Gabapentin analogues for sleep disorders
|
GB2364049A
(en)
*
|
2000-06-28 |
2002-01-16 |
Warner Lambert Co |
Cyclic ketones and their use in the synthesis of amino acids
|
ES2252310T3
(es)
*
|
2000-09-14 |
2006-05-16 |
Grunenthal Gmbh |
Beta-tioaminoacidos.
|
AU2002230398A1
(en)
*
|
2000-10-06 |
2002-04-29 |
Xenoport, Inc. |
Bile-acid conjugates for providing sustained systemic concentrations of drugs
|
AU2002211863A1
(en)
*
|
2000-10-06 |
2002-04-15 |
Xenoport, Inc. |
Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
|
US6620829B2
(en)
*
|
2000-10-17 |
2003-09-16 |
Warner-Lambert Company |
Method of treating noninflammatory cartilage damage
|
IT1319234B1
(it)
*
|
2000-10-23 |
2003-09-26 |
Zambon Spa |
Processo di preparazione di gabapentina.
|
GB2368579A
(en)
*
|
2000-10-31 |
2002-05-08 |
Parke Davis & Co Ltd |
Azole pharmaceutical agents
|
KR20030048105A
(ko)
*
|
2000-11-02 |
2003-06-18 |
테바 파마슈티컬 인더스트리즈 리미티드 |
가바펜틴 중간체의 개선된 제조 방법
|
IL155710A0
(en)
*
|
2000-11-30 |
2003-11-23 |
Pfizer Prod Inc |
Combination of gaba agonists and aldose reductase inhibitors
|
IL155704A0
(en)
*
|
2000-11-30 |
2003-11-23 |
Pfizer Prod Inc |
Combination of gaba agonists and sorbitol dehydrogenase inhibitors
|
IT1319674B1
(it)
*
|
2000-12-01 |
2003-10-23 |
Erregierre Spa |
Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
|
EP1373186A1
(en)
*
|
2001-03-16 |
2004-01-02 |
Solchem Italiana S.p.A |
A process for the preparation of cyclic amino acids
|
ITMI20011132A1
(it)
|
2001-05-29 |
2002-11-29 |
Procos Spa |
Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
|
MXPA03011566A
(es)
*
|
2001-06-11 |
2004-10-28 |
Xenoport Inc |
Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
|
US8048917B2
(en)
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7186855B2
(en)
*
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
WO2002100344A2
(en)
*
|
2001-06-11 |
2002-12-19 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
IL144066A0
(en)
*
|
2001-06-28 |
2002-04-21 |
Bromine Compounds Ltd |
Process for the preparation of 1,1-cyclohexane diacetic monoamide
|
ITMI20011772A1
(it)
|
2001-08-10 |
2003-02-10 |
A M S A Anonima Materie Sint E |
Processo per la preparazione della 2,5-bis-(2,2,2-trifluoroetossi)-n-(2-piperidilmetil)-benzamide(flecainide)
|
EP1423168B1
(en)
*
|
2001-09-03 |
2006-02-08 |
Newron Pharmaceuticals S.p.A. |
Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
|
US6800782B2
(en)
*
|
2001-10-09 |
2004-10-05 |
Warner-Lambert Co. |
Anhydrous crystalline forms of gabapentin
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
US7612112B2
(en)
*
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
ITMI20012750A1
(it)
|
2001-12-21 |
2003-06-21 |
Procos Spa |
Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
|
US20030119908A1
(en)
*
|
2001-12-21 |
2003-06-26 |
Zambon Group S.P.A. |
Stable gabapentin compositions
|
MXPA04004105A
(es)
*
|
2002-01-31 |
2004-11-29 |
Warner Lambert Co |
Metodo de tratamiento de tinnitus.
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US6927036B2
(en)
*
|
2002-02-19 |
2005-08-09 |
Xero Port, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
US7026351B2
(en)
*
|
2002-03-20 |
2006-04-11 |
Xenoport, Inc. |
Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
|
WO2003089403A1
(en)
*
|
2002-04-16 |
2003-10-30 |
Taro Pharmaceutical Industries Ltd. |
Process for preparing gabapentin
|
WO2003094842A2
(en)
*
|
2002-05-07 |
2003-11-20 |
A & D Bioscience, Inc. |
Conjugates comprising central nervous system active drug
|
AU2003243180A1
(en)
*
|
2002-05-17 |
2003-12-12 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
AU2003239752A1
(en)
*
|
2002-06-27 |
2004-01-19 |
Warner-Lambert Company Llc |
Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
|
CA2395931A1
(en)
*
|
2002-08-07 |
2004-02-07 |
Bernard Charles Sherman |
Solid compositions comprising gabapentin having improved stability
|
US7053122B2
(en)
*
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
US20040092522A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Field Mark John |
Synergistic combinations
|
US20040092591A1
(en)
*
|
2002-08-15 |
2004-05-13 |
Blakemore David Clive |
Therapeutic use of fused bicyclic or tricyclic amino acids
|
US7419981B2
(en)
*
|
2002-08-15 |
2008-09-02 |
Pfizer Inc. |
Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
|
US20040092498A1
(en)
*
|
2002-08-16 |
2004-05-13 |
David Blakemore |
Substituted glycine derivatives for use as medicaments
|
ITMI20022071A1
(it)
*
|
2002-10-01 |
2004-04-02 |
Erregierre Spa |
Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
|
US7659305B2
(en)
*
|
2002-10-31 |
2010-02-09 |
Pfizer Inc. |
Therapeutic proline derivatives
|
AU2002356424A1
(en)
*
|
2002-11-18 |
2004-06-15 |
Nicholas Piramal India Limited |
Improved process for preparation of gabapentin
|
AU2002356427A1
(en)
*
|
2002-11-20 |
2004-06-15 |
Sivaramakrishnan Hariharan |
An improved process for the preparation of gabalactam
|
US20040162351A1
(en)
*
|
2002-12-11 |
2004-08-19 |
Gallop Mark A. |
Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
|
WO2004052360A1
(en)
*
|
2002-12-11 |
2004-06-24 |
Xenoport, Inc. |
Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
EP1572187A1
(en)
*
|
2002-12-13 |
2005-09-14 |
Warner-Lambert Company LLC |
Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders
|
US20040180958A1
(en)
*
|
2002-12-13 |
2004-09-16 |
Taylor Charles Price |
Method of treatment
|
PL377286A1
(pl)
*
|
2002-12-13 |
2006-01-23 |
Warner-Lambert Company Llc |
Analogi gabapentyny do włókniako-mięśniakowych i innych pokrewnych zaburzeń
|
ES2341240T3
(es)
|
2002-12-13 |
2010-06-17 |
Warner-Lambert Company Llc |
Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
|
RU2353358C2
(ru)
|
2002-12-13 |
2009-04-27 |
Уорнер-Ламберт Компани Ллс |
Производные прегабалина для лечения приливов
|
GB0301143D0
(en)
*
|
2003-01-17 |
2003-02-19 |
Amedis Pharm Ltd |
Compounds and their use
|
JP2006516275A
(ja)
*
|
2003-01-22 |
2006-06-29 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
シクロプロピルβ−アミノ酸誘導体
|
MXPA05009504A
(es)
*
|
2003-03-07 |
2005-10-18 |
Warner Lambert Co |
Derivados de (-aminoacidos sustituidos con tetrazol y oxadiazolona.
|
WO2004093867A2
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
|
EP1622603A4
(en)
*
|
2003-03-25 |
2010-03-24 |
Kiel Lab Inc |
GABAPENTINIC PHENOLIC ACID SALTS IN SOLID DOSAGE FORMS AND METHODS OF USE
|
WO2004093866A1
(en)
*
|
2003-03-25 |
2004-11-04 |
Kiel Laboratories, Inc. |
Process for preparing phenolic acid salts of gabapentin
|
JP2006522146A
(ja)
*
|
2003-03-31 |
2006-09-28 |
ゼノポート,インコーポレイティド |
Gaba類似体のプロドラッグを使用するのぼせの治療または予防
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
ITMI20030825A1
(it)
*
|
2003-04-18 |
2004-10-19 |
Farchemia Srl |
Procedimento per la preparazione di gabapentin esente da
|
US7439387B2
(en)
*
|
2003-04-21 |
2008-10-21 |
Matrix Laboratories Ltd. |
Process for the preparation of Gabapentin form-II
|
RU2005135454A
(ru)
*
|
2003-05-16 |
2006-06-27 |
Пфайзер Продактс Инк. (Us) |
Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
|
EP1639118A1
(en)
*
|
2003-06-19 |
2006-03-29 |
Pfizer Products Inc. |
Biocatalytic preparation of 1-cyanocyclohexaneacetic acid
|
US7169812B2
(en)
*
|
2003-07-01 |
2007-01-30 |
Medtronic, Inc. |
Process for producing injectable gabapentin compositions
|
WO2005002585A1
(en)
*
|
2003-07-02 |
2005-01-13 |
Warner-Lambert Company Llc |
Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
WO2005046566A2
(en)
*
|
2003-08-04 |
2005-05-26 |
Sun Pharmaceutical Industries Limited |
Stable gabapentin containing composition
|
US20050043407A1
(en)
*
|
2003-08-22 |
2005-02-24 |
Pfizer Inc |
Pharmaceutical composition for the prevention and treatment of addiction in a mammal
|
NZ545884A
(en)
*
|
2003-09-11 |
2010-01-29 |
Xenoport Inc |
Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
|
KR100828218B1
(ko)
*
|
2003-09-12 |
2008-05-07 |
화이자 인코포레이티드 |
알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
|
CN1878546A
(zh)
*
|
2003-09-12 |
2006-12-13 |
沃纳-兰伯特公司 |
治疗抑郁症和焦虑症的包括α-2δ配体和SSRI和/或SNRI的联用药物
|
BRPI0414481A
(pt)
*
|
2003-09-17 |
2006-11-14 |
Xenoport Inc |
métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
|
CA2541752C
(en)
|
2003-10-14 |
2012-01-03 |
Xenoport, Inc. |
Crystalline form of gamma-aminobutyric acid analog
|
ITMI20032165A1
(it)
*
|
2003-11-11 |
2005-05-12 |
Zambon Spa |
Processo di preparazione di gabapentina
|
ES2515092T3
(es)
|
2003-12-11 |
2014-10-29 |
Sunovion Pharmaceuticals Inc. |
Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
|
WO2005082372A1
(en)
*
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
|
US20050187295A1
(en)
*
|
2004-02-19 |
2005-08-25 |
Surendra Kalyan |
Processes for the preparation of gabapentin
|
WO2005087709A1
(en)
*
|
2004-03-17 |
2005-09-22 |
Hikal Limited |
4-t-butylgabapentin and its synthesis
|
ITMI20040579A1
(it)
*
|
2004-03-25 |
2004-06-25 |
Zambon Spa |
Processo di preparazione di gabapentina
|
US20050233010A1
(en)
*
|
2004-04-19 |
2005-10-20 |
Satow Philip M |
Lithium combinations, and uses related thereto
|
AU2005256944A1
(en)
*
|
2004-06-09 |
2006-01-05 |
Pfizer Inc. |
Use of reboxetine for the treatment of pain
|
GB0416228D0
(en)
*
|
2004-07-20 |
2004-08-25 |
Sandoz Ind Products S A |
Process for the preparation of gabapentin
|
GB0419849D0
(en)
*
|
2004-09-07 |
2004-10-13 |
Pfizer Ltd |
Pharmaceutical combination
|
AU2005282028B2
(en)
*
|
2004-09-10 |
2011-03-24 |
Newron Pharmaceuticals S.P.A. |
(halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
|
NZ554737A
(en)
*
|
2004-11-04 |
2011-04-29 |
Xenoport Inc |
Gabapentin prodrug sustained release oral dosage forms
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス,インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
US8378117B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
KR20080050511A
(ko)
*
|
2005-09-23 |
2008-06-05 |
얀센 파마슈티카 엔.브이. |
테트라하이드로-사이클로펜틸 피라졸 카나비노이드모듈레이터
|
RS52195B
(en)
*
|
2005-09-23 |
2012-10-31 |
Janssen Pharmaceutica N.V. |
MODULATOR HEXA HYDROCYCLOHEPTAPIRAZOLE Cannabinoids
|
US8378096B2
(en)
*
|
2005-09-23 |
2013-02-19 |
Janssen Pharmaceutica N.V. |
Hexahydro-cycloheptapyrazole cannabinoid modulators
|
AU2006302659A1
(en)
*
|
2005-09-23 |
2007-04-19 |
Janssen Pharmaceutica, N.V. |
Hexahydro cyclooctyl pyrazole cannabinoid modulators
|
US7825151B2
(en)
*
|
2005-09-23 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Hexahydro-cyclooctyl pyrazole cannabinoid modulators
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
CA2625210A1
(en)
*
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
US20070117858A1
(en)
*
|
2005-11-23 |
2007-05-24 |
Mingde Xia |
Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
EP1979593B1
(en)
*
|
2006-02-03 |
2017-12-06 |
Rolls-Royce Corporation |
Gas turbine engine fuel system with fuel metering valve
|
EP1820502A1
(en)
|
2006-02-10 |
2007-08-22 |
Laboratorios Del Dr. Esteve, S.A. |
Active substance combination comprising azolylcarbinol compounds
|
WO2007095513A1
(en)
*
|
2006-02-14 |
2007-08-23 |
Janssen Pharmaceutica, Nv |
Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
|
CA2640402C
(en)
*
|
2006-03-06 |
2012-01-03 |
Pfizer Products Inc. |
Alpha-2-delta ligands for non-restorative sleep
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20070254911A1
(en)
*
|
2006-03-27 |
2007-11-01 |
Mingde Xia |
Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
|
WO2007112402A1
(en)
*
|
2006-03-27 |
2007-10-04 |
Janssen Pharmaceutica N.V. |
Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
|
EP2026813A2
(en)
|
2006-05-09 |
2009-02-25 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US7442834B2
(en)
*
|
2006-06-12 |
2008-10-28 |
Zhejiang Chiral Medicine Chemicals Co., Ltd. |
Process suitable for industrial scale production of gabapentin
|
EP2038249B1
(en)
*
|
2006-06-30 |
2013-09-11 |
ZaCh System S.p.A. |
Process for preparing gabapentin
|
US7998971B2
(en)
|
2006-09-08 |
2011-08-16 |
Braincells Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EA200970487A1
(ru)
*
|
2006-12-08 |
2009-12-30 |
Ксенопорт, Инк. |
Применение пролекарств аналогов гамк для лечения заболеваний
|
CN101600458A
(zh)
|
2006-12-22 |
2009-12-09 |
瑞蔻达蒂爱尔兰有限公司 |
采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
|
US20100145057A1
(en)
*
|
2007-03-15 |
2010-06-10 |
Sun Pharma Advanced Research Company Ltd. |
Novel prodrugs
|
TW200908957A
(en)
*
|
2007-06-15 |
2009-03-01 |
Xenoport Inc |
Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
|
US7943653B2
(en)
*
|
2007-08-13 |
2011-05-17 |
Janssen Pharmaceutica N.V. |
Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
|
US20090062392A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched gabapentin
|
WO2009061934A1
(en)
*
|
2007-11-06 |
2009-05-14 |
Xenoport, Inc. |
Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
|
WO2009094577A2
(en)
|
2008-01-25 |
2009-07-30 |
Xenoport, Inc. |
Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
|
WO2009094563A2
(en)
|
2008-01-25 |
2009-07-30 |
Xenoport, Inc. |
Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
|
US8062870B2
(en)
*
|
2008-01-25 |
2011-11-22 |
Xenoport, Inc. |
Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
|
EP2116539A1
(en)
|
2008-04-25 |
2009-11-11 |
Laboratorios Del. Dr. Esteve, S.A. |
1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
|
US20100190752A1
(en)
*
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
US8268887B2
(en)
|
2008-10-08 |
2012-09-18 |
Feng Xu |
Drug conjugates and methods of use thereof
|
WO2010099200A1
(en)
|
2009-02-24 |
2010-09-02 |
Nektar Therapeutics |
Oligomer-amino acid conjugates
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20110124705A1
(en)
*
|
2009-11-24 |
2011-05-26 |
Xenoport, Inc. |
Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
US20110130454A1
(en)
*
|
2009-11-24 |
2011-06-02 |
Xenoport, Inc. |
Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
|
EP2509596B1
(en)
|
2009-12-08 |
2019-08-28 |
Case Western Reserve University |
Gamma aminoacids for treating ocular disorders
|
EP2353591A1
(en)
|
2010-02-04 |
2011-08-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
|
EP2368872A1
(en)
|
2010-03-25 |
2011-09-28 |
Serichim S.r.l. |
Process for the preparation of Gabapentin
|
EP2388005A1
(en)
|
2010-05-21 |
2011-11-23 |
Laboratorios Del. Dr. Esteve, S.A. |
Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
|
WO2011151708A1
(en)
|
2010-06-01 |
2011-12-08 |
Rubicon Research Private Limited |
Gastroretentive dosage forms of gaba analogs
|
US8431739B2
(en)
|
2010-06-14 |
2013-04-30 |
Divi's Laboratories, Ltd. |
Process for the preparation of gabapentin
|
KR101786818B1
(ko)
|
2010-07-30 |
2017-10-18 |
도레이 카부시키가이샤 |
신경장애성 동통의 치료제 또는 예방제
|
EP2415471A1
(en)
|
2010-08-03 |
2012-02-08 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in opioid-induced hyperalgesia
|
JP2013216580A
(ja)
*
|
2010-08-06 |
2013-10-24 |
Kyorin Pharmaceutical Co Ltd |
ビシクロ[2.2.2]オクチルアミン誘導体の製造方法
|
EP2524694A1
(en)
|
2011-05-19 |
2012-11-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Use of sigma ligands in diabetes type-2 associated pain
|
EP2530072A1
(en)
|
2011-06-03 |
2012-12-05 |
Lacer, S.A. |
New compounds, synthesis and use thereof in the treatment of pain
|
US9066853B2
(en)
|
2013-01-15 |
2015-06-30 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable fiber
|
ITMI20131757A1
(it)
|
2013-10-22 |
2015-04-23 |
Zach System Spa |
Processo di preparazione di gabapentina
|
US10047042B2
(en)
|
2013-11-01 |
2018-08-14 |
Glytech, Inc. |
Method for producing D-form or L-form amino acid derivative having thiol group
|
CN105873580B
(zh)
|
2013-12-17 |
2020-08-25 |
埃斯蒂维制药有限公司 |
加巴喷丁类化合物与σ受体配体的组合物
|
EP3082782A1
(en)
|
2013-12-17 |
2016-10-26 |
Laboratorios Del. Dr. Esteve, S.A. |
SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
|
EP2923694B1
(en)
|
2014-03-27 |
2018-11-14 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Oral liquid pharmaceutical solution of gabapentin
|
CA3046846A1
(en)
|
2016-12-16 |
2018-06-21 |
Idorsia Pharmaceuticals Ltd |
Pharmaceutical combination comprising a t-type calcium channel blocker
|
US11510903B2
(en)
|
2018-07-04 |
2022-11-29 |
Federico Amezcua Amezcua |
Synergic pharmaceutical composition of the active enantiomer (S)-ketorolac and Gabapentin for the treatment of neuropathic pain
|
US10399926B1
(en)
|
2018-08-01 |
2019-09-03 |
Divi's Laboratories Ltd. |
Process for the preparation of gabapentin
|
WO2020074944A1
(en)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Inositol phosphates for the treatment of ectopic calcification
|
AU2020370758A1
(en)
|
2019-10-25 |
2022-06-02 |
Kyoto University |
Preventative or therapeutic agent for tauopathy
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|